-
Product Insights
NewNet Present Value Model: Processa Pharmaceuticals Inc’s Eniluracil
Empower your strategies with our Net Present Value Model: Processa Pharmaceuticals Inc's Eniluracil report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CS-0159 in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CS-0159 in Primary Sclerosing Cholangitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CS-0159 in Primary Sclerosing Cholangitis Drug Details: CS-0159 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Roducitabine in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Roducitabine in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Roducitabine in Non-Small Cell Lung Cancer Drug Details: Roducitabine is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Roducitabine in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Roducitabine in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Roducitabine in Gallbladder Cancer Drug Details: Roducitabine is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab in Non-Small Cell Lung Cancer Drug Details: Zenocutuzumab (MCLA-128)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eniluracil in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eniluracil in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eniluracil in Metastatic Breast Cancer Drug Details: Eniluracil is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eniluracil in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eniluracil in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eniluracil in Solid Tumor Drug Details: Eniluracil is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eniluracil in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eniluracil in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eniluracil in Pancreatic Cancer Drug Details: Eniluracil is under development for...
-
Product Insights
Gastroparesis – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroparesis - Drugs In Development, 2023’, provides an overview of the Gastroparesis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...